All relevant data are within the manuscript and its Supporting Information files.

Introduction {#sec001}
============

Exercise intolerance is a major manifestation of cardiopulmonary disease. The gold standard for assessment of exercise capacity is cardiopulmonary exercise testing (CPET) with direct measurement of oxygen uptake at peak exercise (VO~2peak~). Reduced VO~2peak~ is associated with increased mortality \[[@pone.0232693.ref001]--[@pone.0232693.ref004]\].

In patients with coronary artery disease (CAD), regional myocardial dysfunction may affect cardiac stroke volume (SV) \[[@pone.0232693.ref005]\]. At submaximal levels of exercise, reduced SV can be compensated for by increased heart rate (HR), but the maximal cardiac output (CO) is reduced. This implies impaired capacity for oxygen transport during exercise \[[@pone.0232693.ref006]\] with reduced VO~2peak~ and functional impairment from cardiovascular limitation in CAD.

In contrast, oxygen transport by the pulmonary system (i.e. ventilation and gas exchange), should not be directly affected by CAD. Residual capacity to increase ventilation and maintained homeostasis of arterial blood gases are typically observed during CPET in patients with CAD \[[@pone.0232693.ref007]\]. Therefore, neither ventilation nor gas exchange are considered to be primary limiting factors of VO~2peak~ in these patients. However, the oxygen transport and utilization chain depends on the integrated cardiovascular and pulmonary response to exercise \[[@pone.0232693.ref008]\] to which the normal pulmonary system may influence overall capacity \[[@pone.0232693.ref009]\].

Due to shared risk factors for disease (i.e. ageing and smoking exposure), cardiopulmonary comorbidity is common in clinical practice. Lung function measures may be reduced in patients with CAD due to concomitant heart failure (HF) \[[@pone.0232693.ref010]--[@pone.0232693.ref014]\] and/or chronic obstructive pulmonary disease (COPD) \[[@pone.0232693.ref015]\]. Reduced forced expiratory lung volume in one second (FEV~1~) and transfer factor of the lung for carbon monoxide (T~L~CO) are associated with reduced exercise capacity in patients with HF and COPD \[[@pone.0232693.ref010], [@pone.0232693.ref014], [@pone.0232693.ref016], [@pone.0232693.ref017]\]. However, it is unknown whether and to what extent normal values of lung function measures are associated with VO~2peak~ in patients with CAD.

The aim of this study was to investigate whether dynamic lung volume, measured by FEV~1~, and lung diffusing capacity, measured by T~L~CO and T~L~CO/alveolar volume (T~L~CO/VA), above lower limits of normal (LLN) are associated with VO~2peak~ in patients with exercise intolerance and CAD. Non-obstructive patients, defined as FEV~1~ and FEV~1~/forced vital capacity (FVC) above LLN, were assessed.

Materials and methods {#sec002}
=====================

Study population {#sec003}
----------------

The study population consists of patients with perceived exercise intolerance referred for evaluation from primary care to a private specialist clinic (Telemark Heart Lung and Blood Institute) in Norway between April 1999 and April 2013.

We included all patients with known CAD, defined as any medical history of myocardial infarction (MI) and/or previous revascularization procedure with percutaneous coronary intervention (PCI) or aortocoronary bypass (ACB), as documented in medical records from evaluation at the CPET clinic (n = 229; 55 women). Data from lung function tests (spirometry and diffusing capacity) and CPET were available.

In order to reduce confounding by concurrent COPD, we excluded 89 patients with potential obstructive ventilatory defect defined as both FEV~1~ and FEV~1~/FVC less than LLN. Predicted values and Z-scores were calculated using the Global Lung Function Initiative (GLI) 2012 software \[[@pone.0232693.ref018]\]. The LLN was defined as the fifth percentile (z-score = -1.645) \[[@pone.0232693.ref019]\]. In four patients reversibility testing was performed. One patient was excluded due to significant reversibility, defined by a postbronchodilator increase in FEV~1~ ≥ 200 ml and 12%.

Furthermore, 18 patients were excluded due to respiratory exchange ratio at peak exercise (RER~peak~) less than or equal to 1.00 indicating potential submaximal effort in this cohort. Six patients were excluded due to CPET performed on treadmill.

Due to missing values on lung diffusing capacity (14 patients), smoking status (6 patients), heart rate at peak exercise (HR~peak~) (1 patient) and pulse oximetry (1 patient), a total of 93 patients remained in the statistical analyses.

Pulmonary function tests {#sec004}
------------------------

Spirometry (Vmax Legacy/Spectra 229; SensorMedics) was performed on the same day and prior to CPET. In the three patients who had reversibility testing performed (non-significant), the highest FEV~1~ from pre- or postbronchodilator measurement was chosen. The procedures followed the American Thoracic Society/European Respiratory Society guidelines \[[@pone.0232693.ref020], [@pone.0232693.ref021]\].

Lung diffusion capacity (Vmax Legacy/Spectra 229; SensorMedics), measured by the single breath method, was performed within four months prior to CPET in all patients. Predicted values and Z-scores of T~L~CO and T~L~CO/VA were calculated using the GLI 2017 software \[[@pone.0232693.ref022]\]. Four patients were outside the valid range (age \> 80 years) and therefore excluded from statistical analyses involving T~L~CO and T~L~CO/VA.

Cardiopulmonary exercise test {#sec005}
-----------------------------

Fitted with a facemask or a mouthpiece and nose clip, depending on patient comfort, incremental symptom-limited exercise was performed on cycle ergometer (ER900; Ergoline). The incremental phase of the test protocol followed an increasing work rate of 15--30 W/min, aiming for test termination after 8--12 minutes.

Oxygen uptake (VO~2~) and carbon dioxide output (VCO~2~) were measured breath by breath (Vmax Legacy/Spectra 229; SensorMedics) and averaged over 20 seconds. The highest 20 second-value of VO~2~ was termed VO~2peak~ and standardized by bodyweight (ml/kg/min). The primary symptom to limit exercise was reported by the patient and characterized as leg discomfort/fatigue, dyspnea, chest pain or other.

Ventilatory reserve (VR) was calculated as VR = 1 − minute ventilation at peak exercise (VE~peak~)/maximal voluntary ventilation (MVV). MVV was estimated by FEV~1~ x 40 \[[@pone.0232693.ref023]\]. Reduced VR was defined as VR less than 15% \[[@pone.0232693.ref007]\]. Heart rate reserve (HRR) was calculated as HRR = 1 − heart rate at peak exercise (HR~peak~)/maximal HR (HR~max~). HR~max~ was estimated by 220---age.

Pulse oximetry (SpO~2~) was measured continuously with a finger probe (Model 340; Palco Labs/8600; Nonin) from rest to peak exercise and the minimum value (SpO~2min~) was recorded. A 12-lead electrocardiogram (ECG) (CardioPerfect MD; CardioControl/CardioSoft Corina; Marquette) was monitored continuously and interpreted in a qualitative manner by an experienced specialist in internal medicine (HJ). Changes during exercise from recordings at rest were characterized as ST segment morphology consistent with ischemia, increasing frequency of ventricular (VES) or supraventricular (SVES) extrasystoles or none.

Statistical analyses {#sec006}
--------------------

Descriptive statistics are reported as mean and standard deviation (SD) or number of observations and percentages.

Mean values of FEV~1Z-score~, T~L~CO~Z-score~ and T~L~CO/VA~Z-score~ above LLN were compared between groups categorized by primary symptom to limit exercise using one-way analysis of variance (ANOVA).

The associations of FEV~1Z-score~, T~L~CO~Z-score~ and T~L~CO/VA~Z-score~ above LLN with VO~2peak~ were estimated in linear regression models including both sexes. The association between FEV~1Z-score~ and VO~2peak~ was estimated in the total sample while the associations of T~L~CO~Z-score~ and T~L~CO/VA~Z-score~ with VO~2peak~ were estimated only in patients aged 80 years or younger with T~L~CO~Z-score~ (n = 75; 17 women) and T~L~CO/VA~Z-score~ (n = 80; 19 women) above LLN, respectively.

Potential confounders were considered and four models are presented: 1) Crude associations; 2) Adjusted for sex, age and body mass index (BMI); 3) Additionally adjusted for smoking status (never, former or current); 4) Additionally adjusted for treatment with systemic beta-blockers (yes or no) and/or inhaled bronchodilators including short and long acting beta2-agonists and/or anticholinergic drugs (yes or no). Beta coefficients (β) and 95% confidence intervals (CI) are presented.

In sensitivity analyses including only patients with exercise induced ECG changes from rest (ischemia or increasing VES and/or SVES), the associations of FEV~1Z-score~ (n = 68), T~L~CO~Z-score~ (n = 55) and T~L~CO/VA~Z-score~ (n = 60) above LLN with VO~2peak~ were estimated with adjustments corresponding to model 4 in the primary analyses.

No violations of assumptions on linear regression were uncovered after assessment by residual plots in all models (Charts in [S2 Output](#pone.0232693.s006){ref-type="supplementary-material"}, Charts in [S3 Output](#pone.0232693.s007){ref-type="supplementary-material"}, Charts in [S4 Output](#pone.0232693.s008){ref-type="supplementary-material"}, Charts in [S5 Output](#pone.0232693.s009){ref-type="supplementary-material"}, Charts in [S6 Output](#pone.0232693.s010){ref-type="supplementary-material"} and Charts in [S7 Output](#pone.0232693.s011){ref-type="supplementary-material"}).

Statistical analyses were performed with IBM SPSS Statistics Version 25 (IBM Corp., Armonk, NY, USA).

Ethics approval {#sec007}
---------------

The Regional Committee for Medical and Health Research Ethics approved this study (REC-Central 2012/673) and the use of anonymous data without written informed consent.

Results {#sec008}
=======

Men and women were of similar age and had similar body mass index (BMI). The majority of patients were former or current smokers (78%), had a medical history of previous PCI or ACB (76%), and were under treatment with a beta-blocker (66%). In the total sample 17% were under treatment with an inhaled bronchodilator at the time of CPET and the proportion was lower in men (11%) than in women (38%). Men had higher FEV~1Z-score~ and (FEV~1~/FVC)~Z-score~ than women. Compared to women, men had higher T~L~CO~Z-score~, similar T~L~CO/VA~Z-score~ and higher VA~Z-score~ ([Table 1](#pone.0232693.t001){ref-type="table"}).

10.1371/journal.pone.0232693.t001

###### Clinical characteristics and lung function measures.

![](pone.0232693.t001){#pone.0232693.t001g}

                                                                      Total (n = 93)   Men (n = 72)   Women (n = 21)
  ------------------------------------------------------------------- ---------------- -------------- ----------------
  Age (years)                                                         65.5±10.3        65.3±11.0      66.2±7.4
  Weight (kg)                                                         84.6±15.0        88.1±13.7      72.5±13.4
  Height (cm)                                                         174.3±8.9        177.7±6.1      162.7±6.6
  BMI (kg/m^2^)                                                       27.7±4.0         27.9±3.8       27.4±4.5
  Smoking status                                                                                      
   Never                                                              20(22)           13(18)         7(33)
   Former                                                             54(58)           44(61)         10(48)
   Current                                                            19(20)           15(21)         4(19)
  CAD status                                                                                          
   MI                                                                 22(24)           19(26)         3(14)
   PCI or ACB                                                         71(76)           53(74)         18(86)
  Systemic beta-blocker                                               61(66)           46(64)         15 (71)
  Inhaled bronchodilator                                              16(17)           8(11)          8(38)
  Lung function measures                                                                              
   FVC (L)                                                            4.07±0.99        4.39±0.86      2.99±0.52
   FVC~Z-score~                                                       -0.06±0.91       -0.08±0.91     0.01±0.92
   FEV~1~ (L)                                                         3.01±0.75        3.25 ±0.65     2.19 ±0.44
   FEV~1Z-score~                                                      -0.29±0.88       -0.27±0.84     -0.36±1.00
   FEV~1~/FVC                                                         0.74±0.05        0.74±0.05      0.73±0.05
   (FEV~1~/FVC)~Z-score~                                              -0.42±0.67       -0.33±0.68     -0.72±0.59
   T~L~CO (mmol/min/kPa)[^a^](#t001fn002){ref-type="table-fn"}        7.67±2.04        8.26±1.88      5.76±1.20
   T~L~CO~Z-score~[^a^](#t001fn002){ref-type="table-fn"}              -0.68±1.09       -0.60±1.08     -0.95±1.10
   T~L~CO/VA (mmol/min/kPa/L)[^a^](#t001fn002){ref-type="table-fn"}   1.36±0.26        1.36±0.27      1.36±0.23
   T~L~CO/VA~Z-score~[^a^](#t001fn002){ref-type="table-fn"}           -0.25±1.14       -0.23±1.18     -0.30±1.04
   VA (L)[^a^](#t001fn002){ref-type="table-fn"}                       5.68±1.25        6.11±1.02      4.29±0.87
   VA~Z-score~[^a^](#t001fn002){ref-type="table-fn"}                  -0.58±1.10       -0.50±1.06     -0.87±1.20

Values are mean ± standard deviation or number (percentage). BMI---body mass index, CAD coronary artery disease, MI---myocardial infarction without revascularization procedure, PCI---percutaneous coronary intervention, ACB---aortocoronary bypass, FVC---forced vital capacity, FEV~1~ ---forced expiratory lung volume in one second, T~L~CO---transfer factor of the lung for carbon monoxide, VA---Alveolar volume.

^a^Patients ≤ 80 years; n = 89; 21 women.

VO~2peak~ was 23.8 ± 6.4 ml/kg/min in men and 19.7 ± 4.4 ml/kg/min in women. RER~peak~ was equal in men and women (1.19 ± 0.11). Preserved VR (VR ≥ 15%) was observed in all but six patients (6%). SpO~2min~ was high and similar in men (95.8 ± 1.5%) and women (96.2 ± 1.2%). Only three patients had SpO~2min~ less than 94% and none had SpO~2min~ less than 91%. CPET was terminated due to chest pain in 8%, dyspnea in 34% and general fatigue/leg discomfort in 48% of the patients. ECG changes from rest were observed in the majority of patients (73%). Increasing VES and/or SVES during exercise were more frequent than ischemia (55% vs. 18%) ([Table 2](#pone.0232693.t002){ref-type="table"}).

10.1371/journal.pone.0232693.t002

###### Symptom limited, incremental cardiopulmonary exercise test measures.

![](pone.0232693.t002){#pone.0232693.t002g}

                                                 Total (n = 93)   Men (n = 72)   Women (n = 21)
  ---------------------------------------------- ---------------- -------------- ----------------
  VO~2peak~ (ml/kg/min)                          22.9±6.3         23.8±6.4       19.7±4.4
  VO~2peak~ (L/min)                              1.93±0.60        2.08±0.57      1.42±0.37
  VE~peak~ (L/min)                               81.0±23.6        87.2±22.2      59.7±13.8
  MVV (L/min)                                    120.5±30.0       130.0±25.8     87.7±17.6
  RER~peak~                                      1.19±0.11        1.19±0.11      1.19±0.11
  VR (%)                                         32±14            32±13          30±17
  Preserved VR (VR ≥ 15%)                        87(94)           69(96)         18(86)
  HRR (%)                                        11±13            11±14          12±12
  SpO~2min~ (%)                                  95.9±1.4         95.8±1.5       96.2±1.2
  Reason for test termination                                                    
   Chest pain                                    7(8)             6(8)           1(4)
   Dyspnea                                       32(34)           22(31)         10(48)
   Fatigue / leg discomfort                      45(48)           35(49)         10(48)
   Other[^a^](#t002fn002){ref-type="table-fn"}   9(10)            9(13)          0(0)
  ECG changes from baseline                                                      
   None[^b^](#t002fn003){ref-type="table-fn"}    25(27)           18(25)         7(33)
   VES / SVES                                    51(55)           41(57)         10(48)
   Ischemia                                      17(18)           13(18)         4(19)

Values are mean ± standard deviation or number (percentage). VO~2peak~---peak oxygen uptake, VE~peak~---peak minute ventilation, MVV---maximal voluntary ventilation, RER~peak~---peak respiratory exchange ratio, VR---Ventilatory reserve, HRR---heart rate reserve, SpO2---minimum value of pulse oximetry, ECG---electrocardiogram, VES---ventricular extrasystoles, SVES---supraventricular extrasystoles.

^a^ECG or blood pressure changes (n = 5), vertigo/headache (n = 2), discomfort from bicycle seat (n = 1), post-operative concerns (n = 1).

^b^Normal ECG (n = 23), atrial fibrillation (n = 2).

Mean values of FEV~1Z-score~, T~L~CO~Z-score~ and T~L~CO/VA~Z-score~ above LLN did not differ statistically by primary symptom to limit exercise (P-value for F-test 0.167, 0.207 and 0.612, respectively). Output of the ANOVA is shown in [S1 Output](#pone.0232693.s005){ref-type="supplementary-material"}.

FEV~1Z-score~, T~L~CO~Z-score~ and T~L~CO/VA~Z-score~ above LLN were positively associated with VO~2peak~. Simple scatter plots of FEV~1Z-score~, T~L~CO~Z-score~ and T~L~CO/VA~Z-score~ by VO~2peak~ are shown in [S1](#pone.0232693.s002){ref-type="supplementary-material"}, [S2](#pone.0232693.s003){ref-type="supplementary-material"} and [S3](#pone.0232693.s004){ref-type="supplementary-material"} Figs, respectively. Adjustments did not influence the point estimates (β) for FEV~1Z-score~ and T~L~CO~Z-score~ but strengthened the association between T~L~CO/VA~Z-score~ and VO~2peak~. On average, one SD increase in FEV~1~ (model 4), T~L~CO (model 4) and T~L~CO/VA (model 4) was associated with 1.4 (95% CI 0.2, 2.6), 2.6 (95% CI 1.2, 4.0) and 1.3 (95% CI 0.2, 2.5) ml/kg/min higher VO~2peak~, respectively ([Table 3](#pone.0232693.t003){ref-type="table"}). Output of the multiple regression analyses (model 4), are shown in [S2](#pone.0232693.s006){ref-type="supplementary-material"}, [S3](#pone.0232693.s007){ref-type="supplementary-material"} and [S4](#pone.0232693.s008){ref-type="supplementary-material"} Outputs, respectively.

10.1371/journal.pone.0232693.t003

###### Associations between lung function measures above LLN and VO~2peak~ (ml/kg/min) in non-obstructive patients with coronary artery disease.

![](pone.0232693.t003){#pone.0232693.t003g}

                       Model 1[^a^](#t003fn002){ref-type="table-fn"}   Model 2[^b^](#t003fn003){ref-type="table-fn"}   Model 3[^c^](#t003fn004){ref-type="table-fn"}   Model 4[^d^](#t003fn005){ref-type="table-fn"}                                     
  -------------------- ----------------------------------------------- ----------------------------------------------- ----------------------------------------------- ----------------------------------------------- ---------- ----- ---------- ----- ----------
  FEV~1Z-score~        93                                              1.4                                             -0.1, 2.8                                       1.5                                             0.3, 2.7   1.4   0.2, 2.6   1.4   0.2, 2.6
  T~L~CO~Z-score~      75                                              2.5                                             0.8, 4.2                                        2.7                                             1.3, 4.1   2.6   1.3, 4.0   2.6   1.2, 4.0
  T~L~CO/VA~Z-score~   80                                              1.0                                             -0.3, 2.4                                       1.5                                             0.4, 2.7   1.3   0.1, 2.5   1.3   0.2, 2.5

LLN---lower limit of normal, VO~2peak~---peak oxygen uptake, β---regression coefficient, CI---confidence interval, FEV~1Z-score~---forced expiratory lung volume in one second Z-score, T~L~CO~Z-score~---transfer factor of the lung for carbon monoxide Z-score.

^a^Crude model.

^b^Adjusted for sex, age (years) and body mass index (BMI) (kg/m^2^).

^c^Adjusted for sex, age, BMI and smoking status (never, former, current).

^d^Adjusted for sex, age, BMI, smoking status, systemic beta-blocker (yes, no) and inhaled bronchodilator (yes, no).

In the sensitivity analyses including only patients with exercise induced ECG changes from rest, FEV~1Z-score~, T~L~CO~Z-score\ and~ T~L~CO/VA~Z-score~ above LLN were positively associated with VO~2peak~ (β = 1.9 (95% CI 0.6, 3.1), 2.5 (95% CI 1.0, 4.0) and 1.5 (95% CI 0.1, 2.9), respectively). Output of the multiple regression analyses are shown in [S5](#pone.0232693.s009){ref-type="supplementary-material"}, [S6](#pone.0232693.s010){ref-type="supplementary-material"} and [S7](#pone.0232693.s011){ref-type="supplementary-material"} Outputs, respectively.

Discussion {#sec009}
==========

In this study we found dynamic lung volume, measured by FEV~1~ and lung diffusing capacity, measured by both T~L~CO and T~L~CO/VA, above LLN to be positively associated with VO~2peak~ in non-obstructive patients with CAD and exercise intolerance from cardiovascular limitation.

We have previously reported positive associations between lung function measures and VO~2peak~, among those with normal dynamic lung volumes in healthy elderly subjects \[[@pone.0232693.ref024]\], and in a healthy general population of a wide age-span \[[@pone.0232693.ref025]\]. However, this is the first study to report the associations between normal values of lung function measures and VO~2peak~ in patients with CAD.

Ventilatory contribution to exercise limitation has been suggested in healthy individuals characterized by high metabolic demands \[[@pone.0232693.ref026]\]. In highly trained athletes performing exercise at sea level, high VO~2peak~ may require levels of ventilation approaching maximal capacity, leading to exercise induced expiratory flow limitation, dynamic hyperinflation and mechanical constraints on tidal volume expansion. Inadequate hyperventilatory responses in athletes may interact with increased heterogeneity in distribution of ventilation/perfusion ratios and/or diffusion limitation causing exercise induced arterial hypoxemia (EIAH) \[[@pone.0232693.ref027]\]. Compared to healthy subjects and trained athletes in particular, patients with CAD may have exercise intolerance \[[@pone.0232693.ref006]\] and reduced VO~2peak~ due to symptomatic disease and/or deconditioning from physical inactivity. Lower VO~2peak~ from cardiovascular limitation reduces the need for oxygen transport by the pulmonary system. In this study the patients had high RER~peak~ (1.19 ± 0.11) consistent with physiological responses to exercise characteristic of cardiovascular limitation. Additionally we found preserved VR, indicating low ventilatory demand at peak exercise relative to maximal ventilatory capacity, in the majority of patients (94%) as well as high SpO~2min~ (95.9 ± 1.4%). Therefore, the positive associations of FEV~1~, T~L~CO and T~L~CO/VA above LLN with VO~2peak~ are not likely to be explained by ventilatory limitation or abnormal gas exchange in patients with CAD.

Several reviews have discussed mechanisms by which the normal respiratory system may influence exercise capacity. Bye et al \[[@pone.0232693.ref028]\] presented studies arguing a potential effect of the oxygen cost of breathing on overall exercise performance. Amman et al \[[@pone.0232693.ref009]\] and Dempsey et al \[[@pone.0232693.ref029]\] addressed the possibility that sympathetically mediated vasoconstriction may direct blood flow away from peripheral muscles and towards respiratory muscles during high intensity exercise, i.e. the respiratory muscle metaboreflex, and that changes in intrathoracic pressure may affect CO. The effects of such potential underlying mechanisms are currently unknown in patients with CAD. However, finding positive associations of FEV~1~, T~L~CO and T~L~CO/VA above LLN with VO~2peak~ in this study, we may hypothesize exercise induced interactions between the pulmonary and the cardiovascular system, affecting overall capacity of the oxygen transport chain even when lung function is normal in patients with CAD and exercise intolerance from cardiovascular limitation.

We found that one SD increase in FEV~1~, T~L~CO and T~L~CO/VA above LLN were associated with 1.4 (95% CI 0.2, 2.6), 2.6 (95% CI 1.2, 4.0) and 1.3 (95% CI 0.2, 2.5) ml/kg/min higher VO~2peak~, respectively. Keteyian et al \[[@pone.0232693.ref001]\] reported approximately 15% decrease in risk of mortality per ml/kg/min increase in VO~2peak~ in women and men with CAD. Although we did not study the association between lung function measures and mortality, a potential clinical importance of within normal variations in dynamic lung volumes and lung diffusing capacity may be hypothesized. We propose that future studies of exercise capacity in CAD should include lung function variables and address potential mechanisms underlying the associations we report.

The strengths of this study include evaluation of exercise capacity by direct measurement of VO~2~ from CPET. Additionally, normal values of FEV~1~, T~L~CO and T~L~CO/VA were defined by Z-scores taking into account sex, age and height related variance. The GLI-2012 reference equations, used to calculate the LLN of FEV~1~, have been validated for the Norwegian population \[[@pone.0232693.ref030]\]. Adjustment for sex, age and BMI did not influence the associations of FEV~1Z-score~ and T~L~CO~Z-score~ with VO~2peak~, but strengthened the association between T~L~CO/VA~Z-score~ and VO~2peak~ possibly due to negative confounding by BMI. We found no confounding effects of smoking status, treatment with systemic beta-blockers or inhaled bronchodilators. Still, residual confounding cannot be ruled out.

There are limitations to this study. Patients referred from primary care to a specialist clinic for evaluation of exercise intolerance, may differ in disease burden from non-obstructive patients with CAD in general. The generalizability of the study findings is therefore uncertain. However, this is a real-life study of patients that may represent a challenging group for the general practitioners, and are thus of interest from a clinical perspective.

A rather high proportion of these non-obstructive patients were under treatment with inhaled bronchodilators (17%). This may be explained by treatment trials initiated by the general practitioners or from the use of FEV~1~/FVC ratio less than 70% as a diagnostic criteria for COPD, which may lead to over-diagnosis of COPD among elderly compared to the use of Z-scores \[[@pone.0232693.ref031]\]. In patients with reduced lung function from COPD, associations between degree of dyspnea and indices of ventilatory limitation to exercise have been reported \[[@pone.0232693.ref032]\]. In contrast, we did not find FEV~1Z-score~, T~L~CO~Z-score~ or T~L~CO/VA~Z-score~ above LLN to be associated with the primary symptom to limit exercise in this cohort of patients with CAD and a physiological response to exercise characterized by cardiovascular limitation.

The broadly defined inclusion criteria of known CAD may have resulted in a heterogeneous sample, consisting of patients with a range of coronary pathology, from fully re-vascularized arteries to widespread ischemic substrates. Consequently, myocardial ischemia may not have been central to cardiovascular limitation in all patients. Comprehensive evaluation of individual CPET responses including oxygen pulse (O~2pulse~) vs. time, HR vs. VO~2~ and VO~2~/work rate (WR) slope would likely have contributed to distinguish ischemic from non-ischemic physiologic pattern of cardiovascular limitation \[[@pone.0232693.ref033]\]. Unfortunately, only data obtained at maximal exercise were available due to technical problems after the initial data extraction process. However, compared to the main analyses, the sensitivity analyses showed similar associations of FEV~1Z-score~, T~L~CO~Z-score~ and T~L~CO/VA~Z-score~ above LLN with VO~2peak~ among patients with exercise induced ECG changes from rest (ST segment morphology or increased frequency of extrasystoles) suggestive of myocardial ischemia.

Assessments of left ventricular function were not available. Lung function abnormalities are frequent in both HF patients with preserved (HFPEF) \[[@pone.0232693.ref012]\] and reduced ejection fraction \[[@pone.0232693.ref014]\]. Puri et al \[[@pone.0232693.ref010]\] reported reduced T~L~CO in patients with HF compared to normal controls and lower T~L~CO in more severe disease. Although we excluded subjects with FEV~1~, T~L~CO and T~L~CO/VA less than LLN in the analyses of associations with VO~2peak~, confounding by less severe HF cannot be ruled out. Explorative analyses including standard non-invasive CPET measures of ventilatory efficiency could potentially have contributed to further approach of exercise induced cardiopulmonary interactions in CAD. Unfortunately, ventilatory equivalents for CO~2~ (absolute values at anaerobe threshold and/or slope prior to ventilatory compensation point) were not available due to the aforementioned technical problems.

In this study, we lacked measures from arterial blood gasses. SpO~2~ is considered useful for monitoring \[[@pone.0232693.ref007]\], but the arterial O~2~ partial pressure (PaO~2~) and the alveolar---arterial difference in O~2~ partial pressure (A-aDO~2~) are more accurate measures of gas exchange abnormalities during exercise \[[@pone.0232693.ref027]\]. Additionally, measurements of lung diffusing capacity were not adjusted for individual hemoglobin concentrations leading to potential confounding on the associations of T~L~CO~Z-score~ and T~L~CO/VA~Z-score~ with VO~2peak~.

The true maximal oxygen uptake (VO~2max~), may have been underestimated by VO~2peak~, as the latter is sensitive to patient effort \[[@pone.0232693.ref034]\]. Of the secondary criteria to indicate adequate patient effort \[[@pone.0232693.ref007], [@pone.0232693.ref035]\] we used RER~peak~, as HRR was considered less reliable due to treatment with systemic beta-blockers in the majority of patients (66%). Patients with RER~peak~ less than or equal to 1.00 were excluded, but the precision of the estimates may have been influenced. Finally, the cross-sectional design of this study does not permit conclusions on causality.

Conclusions {#sec010}
===========

Dynamic lung volume, measured by FEV~1~ and lung diffusing capacity, measured by T~L~CO and T~L~CO/VA, above LLN are positively associated with VO~2peak~ in non-obstructive patients with CAD and exercise intolerance from cardiovascular limitation. Lung function variables should be considered for inclusion in future studies of exercise capacity in CAD. If causality can be established, the results may imply a clinically significant influence of normal lung function on exercise capacity in these patients.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This study assessed the association of lung function on peak oxygen consumption in patients with coronary artery disease who were within the normal range of lung function. An association was found between higher spirometric variables and TLCO and VO2peak. My comments and suggestions are as follows:

1\) A large issue that I have with this analysis is the lack of consideration for obesity and its effect on the outcome of all of the testing variables.

\(a\) When the VO2peak is only expressed in mL/kg/min (ABW) this is going to affect the interpretation most in those of non-IBW. In order to explore the VO2peak variable fully, it would be important to additionally include the L/min and some %predicted equation (e.g. Wasserman/Hansen, Jones). In doing this, not only is body weight addressed, but the effect of age and gender are accounted.

\(b\) Spirometry is going to be affected by body mass, and the vital capacity (and requisitely FEV1) will progressively lower with increasing weight. In some patients with symptoms and signs of obstructive lung disease (e.g. emphysema on imaging), this reduction in FVC has been shown to "falsely normalize" the FEV1/FVC ratio (and thus the diagnosis of obstructive lung disease alludes this population even though they may have underlying lung/airway disease). Often, the reduction in FVC is not enough to exclude them from the normal range, and this population could easily be present in your cohort (especially given the number of active smokers and those on bronchodilator therapy for some reason).

\(c\) TLCO can be affected by obesity given its effect on the VA component of the equation. Depending on the extent of obesity, the TLCO can be slightly low/low-normal, but the KCO will be elevated in this population. Controlling for weight in the analysis and including the relationship to the KCO would be helpful.

2\) There is no mention of the extent of heart disease in this population, other than a non-standardized diagnosis of CAD. Obviously, variation in both systolic and diastolic function and any underlying pulmonary hypertension will significantly affect VO2peak - and lung function testing to a variable degree (especially TLCO). While I understand that this data may not be available, its absence (as well as other important CPET cardiac parameters) limits the ability to conclude that variations in normal lung function are the reason for differences in VO2peak.

3\) Non-invasive measures of ventilatory efficiency are not reported (e.g. nadir VE/VCO2 and/or VE/VCO2 slope prior to the VCP) and should be reported as a standard CPET parameter, as well as to related to the overall test. For example, to gain further insight (and possibly overcome a lack of other data -- such as echocardiogram data) you could look into ventilatory efficiency vs. reason for test cessation, VO2peak, lung function testing, etc. Also, as above, even if measures of ventilatory efficiency were available, they would be difficult to interpret without some knowledge of the degree of cardiac dysfunction and/or pulmonary vascular disease.

4\) There are no lung volumes reported, which is a recognized limitation of the available data. However, this information would be very helpful in that it could put several aspects of the spirometry and TLCO into context (e.g. effect of overall lung volume (i.e. potential early restrictive disease) on outcomes, the presence of baseline air trapping, the obliteration of the ERV in obesity, etc.). Again, while I understand why this data is not available, its absence limits the ability to draw significant conclusions.

5\) There are no reported CPET parameters that would indicate operating lung volumes during exercise (e.g. loops looking at dynamic EELV change during the test, simple ICs measured during the test looking for dynamic hyperinflation). These would be useful to further examine if and why lower lung function may lead to lower VO2peak in this population.

6\) It would be helpful to know if lung function correlated with reason for test stoppage -- one would presume that a higher proportion of those with lower VO2peaks due to lower lung function would have stopped due to dyspnea.

7\) As with several of the points above, it is recognized that this data is not available - but the lack of O2 pulse data and chronotropic slopes are a problem since they would provide important insights for variations in VO2peak, the contributions of underlying cardiac dysfunction, and the relative effects of BB use.

In the end, I think that the lack of inclusion in the analyses of such a large amount of important data that could affect VO2peak limits the ability to draw conclusions on the association of normal range lung function variations and VO2.

Reviewer \#2: Thank you for the opportunity to review this manuscript. The authors are to be commended for their production of a well-written and interesting study. The purpose of this study was to examine in a group of coronary artery disease (CAD) patients the relationship between individuals with 'normal' lung function (FEV1) and gas exchange (TLCO) and peak oxygen uptake (V̇O2peak). This work continues of from work previously published by the group in healthy older individuals. Overall I think this manuscript provides further important data on the importance of a potential pulmonary contribution to V̇O2peak despite individuals have essentially normal resting lung function and diffusion capacity. I have outlined some minor and specific comments for the authors to consider below. In particular I think it is important to not rule out changes that occur during exercise which may limit peak exercise performance.

Minor Comments

1\. What about the changes in lung function and diffusion capacity during exercise -- have the authors considered these as a potential limitation -- despite normal resting values?

a\. Whilst the authors found that resting ventilatory reserve was not limited what about other possible ventilatory limitations during exercise such as expiratory flow limitation and or dynamic hyperinflation that may explain the ventilatory limitation? Whilst these dynamic changes were not recorded during the study -- could they have played a part in the limitation.

b\. Likewise whilst resting TLCO appeared normal -what about the potential limitations of pulmonary capillary blood volume (VC) and alveolar-capillary conductance (DM) at rest and during exercise. Changes in pulmonary diffusion during exercise have been shown to be related to exercise capacity in heart failure with reduced (HFrEF) and preserved (HFpEF) exercise capacity (- see Olson et al J Car Failure, 2006. 299-306; and JACC Heart Failure, 2016. 490-8). Whilst this is in well-defined HF populations, blunted changes in TLCO do occur during exercise which may account for some degree of limitation. Appreciate the authors did not make these measurements during exercise, these dynamic changes (like those of lung function) may have played a part in the limitation.

2\. The a priori models tested included age and height. Whilst the body mass index appears normal, what about the impact of obesity -- could this not be a confounder, particularly in a coronary artery disease (CAD) population where this is indeed a risk factor?

Specific Comments

1\. Line 103: Was reversibility testing performed on all participants? If reversibility was detected were these participants excluded as this would have suggested presence of underlying obstructive disease?

2\. Please provide the end exercise RPE data -- was this different between groups?

3\. What was the range of V̇O2peak data and the range of FEV1/DLCO data. Recommend that the authors provide a figure of the relationship between V̇O2peak and FEV1/DLCO.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and<http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Response:

In the current version of the manuscript, corrections have been made in order to meet PLOS ONE\`s style requirements.

2\. During your revisions, please note that a simple title correction is required: the word \"within\" should be removed from the title. Please ensure this is updated in the manuscript file and the online submission information.

Response:

Corrected.

3\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.

Response:

Captions have now been included.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

Comments to the Author

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This study assessed the association of lung function on peak oxygen consumption in patients with coronary artery disease who were within the normal range of lung function. An association was found between higher spirometric variables and TLCO and VO2peak. My comments and suggestions are as follows:

1\) A large issue that I have with this analysis is the lack of consideration for obesity and its effect on the outcome of all of the testing variables.

\(a\) When the VO2peak is only expressed in mL/kg/min (ABW) this is going to affect the interpretation most in those of non-IBW. In order to explore the VO2peak variable fully, it would be important to additionally include the L/min and some %predicted equation (e.g. Wasserman/Hansen, Jones). In doing this, not only is body weight addressed, but the effect of age and gender are accounted.

\(b\) Spirometry is going to be affected by body mass, and the vital capacity (and requisitely FEV1) will progressively lower with increasing weight. In some patients with symptoms and signs of obstructive lung disease (e.g. emphysema on imaging), this reduction in FVC has been shown to "falsely normalize" the FEV1/FVC ratio (and thus the diagnosis of obstructive lung disease alludes this population even though they may have underlying lung/airway disease). Often, the reduction in FVC is not enough to exclude them from the normal range, and this population could easily be present in your cohort (especially given the number of active smokers and those on bronchodilator therapy for some reason).

\(c\) TLCO can be affected by obesity given its effect on the VA component of the equation. Depending on the extent of obesity, the TLCO can be slightly low/low-normal, but the KCO will be elevated in this population. Controlling for weight in the analysis and including the relationship to the KCO would be helpful.

Response:

As suggested by the reviewer, we have in the revised version of the manuscript, adjusted the analyses for weight by exchanging the height variable against BMI as a covariate (Materials and methods, Statistical analyses, page 8, line 148 -- 149:

"Potential confounders were considered and four models are presented: 1) Crude associations; 2) Adjusted for sex, age and body mass index (BMI)"

Additionally, we have included VO2peak also expressed as L/min in the descriptive statistics (Results, Table 2, page 11).Including percent predicted of VO2peak as a response variable in the regression analyses was initially contemplated, but avoided due to the following considerations:

Firstly, there are no valid Norwegian reference values applicable for our study population performing CPET on cycle ergometer. Those developed cover treadmill, which will give 5-10% higher reference values.

Secondly, commonly used and recommended reference equations would imply extrapolation in the older patients in our sample with age above the valid range (27% of the sample if using Hansen and coworkers and 36% if using Jones and coworkers reference equations).

Thirdly, application of VO2peak percent predicted as a response variable in the regression analyses may also be less interpretable than absolute values. In this study, explanatory variables are expressed by z-scores; taking into account age, sex and height related variance. Accordingly, changes of one unit in any explanatory variable are comparable between men and women as well as younger and older patients. In contrast, any corresponding change in VO2peak percent predicted may not reflect a comparable change in functional capacity between patients given potential sex and age related differences in variance.

In the revised version of the manuscript we have therefore not included VO2peak percent predicted. However, we are open for discussion on this and will include this variable if the reviewer still want us to do so.

We have included TLCO/VA (KCO) as an explanatory variable in the analyses as required by the reviewer. Table 1 is also updated accordingly including both TLCO/VA and VA (Results, page 10).

2\) There is no mention of the extent of heart disease in this population, other than a non-standardized diagnosis of CAD. Obviously, variation in both systolic and diastolic function and any underlying pulmonary hypertension will significantly affect VO2peak - and lung function testing to a variable degree (especially TLCO). While I understand that this data may not be available, its absence (as well as other important CPET cardiac parameters) limits the ability to conclude that variations in normal lung function are the reason for differences in VO2peak.

Response:

The reviewer addresses a highly relevant point. We certainly agree that heart failure (HF) may confound the associations between lung function measures and VO2peak. This limitation is acknowledged by the following statement (Discussion, page 18, line 311 -- 316):

"Assessments of left ventricular function were not available. Lung function abnormalities are frequent in both HF patients with preserved (HFPEF) \[12\] and reduced ejection fraction \[14\]. Puri et al \[10\] reported reduced TLCO in patients with HF compared to normal controls and lower TLCO in more severe disease. Although we excluded subjects with FEV1 and TLCO less than LLN in the analyses of associations with VO2peak, confounding by less severe HF cannot be ruled out."

Furthermore, we advise against definitive conclusions on causality in this observational study (Discussion, page 18, line 332):

"Finally, the cross-sectional design of this study does not permit conclusions on causality."

And point out implied reservations (Conclusion, page 19, line 338 -- 340):

"If causality can be established, the results may imply a clinically significant influence of normal lung function on exercise capacity in these patients."

3\) Non-invasive measures of ventilatory efficiency are not reported (e.g. nadir VE/VCO2 and/or VE/VCO2 slope prior to the VCP) and should be reported as a standard CPET parameter, as well as to related to the overall test. For example, to gain further insight (and possibly overcome a lack of other data -- such as echocardiogram data) you could look into ventilatory efficiency vs. reason for test cessation, VO2peak, lung function testing, etc. Also, as above, even if measures of ventilatory efficiency were available, they would be difficult to interpret without some knowledge of the degree of cardiac dysfunction and/or pulmonary vascular disease.

Response:

We agree with the reviewer that assessment of ventilatory efficiency, by non-invasive measures, is standard and useful in the clinical evaluation of individual CPET responses.

In pulmonary disease, ventilatory inefficiency may indicate increased dead space ventilation and V/Q heterogeneity due to nonuniform ventilation (airway disease) and/or nonuniform perfusion (lung parenchyma disease/pulmonary vascular disease). The resultant increased ventilatory demand, and potentially enhanced dynamic hyperinflation in airway obstruction/expiratory flow limitation, may lead to restriction of tidal volume expansion and ventilatory limitation.

We believe that ventilatory limitation is unlikely in this study population; caracterized by normal dynamic lung volumes/ventilatory capacity and low metabolic demand (low VO2peak) due to cardiovascular functional limitation (Discussion, page 15, line 247 -- 254):

"Lower VO2peak from cardiovascular limitation reduces the need for oxygen transport by the pulmonary system. In this study the patients had high RER (1.19 ± 0.11) consistent with physiological responses to exercise characteristic of cardiovascular limitation. Additionally we found preserved VR, indicating low ventilatory demand at peak exercise relative to maximal ventilatory capacity, in the majority of patients (94%) as well as high SpO2min (95.9 ± 1.4%). Therefore, the positive associations of FEV1, TLCO and TLCO/VA above LLN with VO2peak are not likely to be explained by ventilatory limitation or abnormal gas exchange in patients with CAD."

Furthermore, non-invasive measures of ventilatory efficiency are well known prognostic markers in patients with heart failure. Although any associations of nadir VE/VCO2 and/or VE/VCO2 slope prior to VCP with lung function measures and VO2peak would not permit conclusions on confounding by heart failure on the reported associations between lung function measures above LLN and VO2peak, we agree that exploratory analyses including variables of ventilatory efficiency would have been valuable and have revised accordingly (Discussion, page 18, line 316 -- 318):

"Explorative analyses including standard non-invasive CPET measures of ventilatory efficiency could potentially have contributed to further approach of exercise induced cardiopulmonary interactions in CAD."

Unfortunately, measures of ventilatory efficiency are not available due to technical, software related problems in the initial data extraction process. We have acknowledged this in the revised version of the manuscript (Discussion, page 18, line 318 -- 320):

Unfortunately, ventilatory equivalents for CO2 (absolute values at anaerobe threshold and/or slope prior to ventilatory compensation point) were not available due to the aforementioned technical problems"

4\) There are no lung volumes reported, which is a recognized limitation of the available data. However, this information would be very helpful in that it could put several aspects of the spirometry and TLCO into context (e.g. effect of overall lung volume (i.e. potential early restrictive disease) on outcomes, the presence of baseline air trapping, the obliteration of the ERV in obesity, etc.). Again, while I understand why this data is not available, its absence limits the ability to draw significant conclusions.

Response:

We certainly recognize that restrictive ventilatory defects are defined by low TLC and that static lung volumes may uncover obstructive redistribution when FEV1/FVC is normal. As pointed out by the reviewer, static lung volume measures would have added valuable information to this study.

On the other hand, both true restriction and obstruction, obscured by normal FEV1/FVC, are unlikely when FVC is normal. In this study only one patient had FVC below LLN, defined by the fifth percentile. Accordingly, both restriction and obstruction are unlikely given the constellation of normal FVC, FEV1 and FEV1/FVC. Thus, lack of static lung volumes should not represent a major limitation in this study.

5\) There are no reported CPET parameters that would indicate operating lung volumes during exercise (e.g. loops looking at dynamic EELV change during the test, simple ICs measured during the test looking for dynamic hyperinflation). These would be useful to further examine if and why lower lung function may lead to lower VO2peak in this population.

Response:

Exercised induced expiratory flow limitation with dynamic hyperinflation and restrictive limitation of tidal volume expansion may occur in subjects with normal dynamic lung volumes when metabolic demands are high. Relative hypoventilation is a known potential mechanism of exercise induced arterial hypoxemia (EIAH) observed in athletes with training induced high cardiac efficiency.

In agreement with the reviewer, we acknowledge that measures addressing dynamic hyperinflation may have added value and would have been included if available. However, in our study population, characterized by low metabolic demands from cardiovascular limitation, we consider exercise induced expiratory flow limitation unlikely given normal dynamic lung volumes (ventilatory capacity) and low VO2peak.

We have revised the manuscript to extend this argument (Discussion, page 15, line 238 -- 254):

"Ventilatory contribution to exercise limitation has been suggested in healthy individuals characterized by high metabolic demands \[26\]. In highly trained athletes performing exercise at sea level, high VO2peak may require levels of ventilation approaching maximal capacity, leading to exercise induced expiratory flow limitation, dynamic hyperinflation and mechanical constraints on tidal volume expansion. Inadequate hyperventilatory responses in athletes may interact with increased heterogeneity in distribution of ventilation/perfusion ratios and/or diffusion limitation causing exercise induced arterial hypoxemia (EIAH) \[27\]. Compared to healthy subjects and trained athletes in particular, patients with CAD may have exercise intolerance \[6\] and reduced VO2peak due to symptomatic disease and/or deconditioning from physical inactivity. Lower VO2peak from cardiovascular limitation reduces the need for oxygen transport by the pulmonary system. In this study the patients had high RERpeak (1.19 ± 0.11) consistent with physiological responses to exercise characteristic of cardiovascular limitation. Additionally we found preserved VR, indicating low ventilatory demand at peak exercise relative to maximal ventilatory capacity, in the majority of patients (94%) as well as high SpO2min (95.9 ± 1.4%). Therefore, the positive associations of FEV1, TLCO and TLCO/VA above LLN with VO2peak are not likely to be explained by ventilatory limitation or abnormal gas exchange in patients with CAD."

6\) It would be helpful to know if lung function correlated with reason for test stoppage -- one would presume that a higher proportion of those with lower VO2peaks due to lower lung function would have stopped due to dyspnea.

Response:

In this study, we argue that patients with CAD, exercise intolerance from cardiovascular limitation and normal ventilatory capacity are not ventilatory limited. Under this assumption, we would not expect associations between dyspnoe and lung function measures in this cohort. In contrast, correlation between dyspnea and ventilatory limitation has been well documented in patients with COPD.

Associations between reason for test stoppage and lung function measures were not defined research questions, but intrigued by the reviewers comment, we agree that additional analyses are justified (Material and methods, Statistical analyses, page 8, line 139 -- 141):

"Mean values of FEV1Z-score, TLCOZ-score and TLCO/VAZ-score above LLN were compared between groups categorized by primary symptom to limit exercise using one-way analysis of variance (ANOVA)."

With corresponding results (Results, page 13, line 201 - 203):

"Mean values of FEV1Z-score, TLCOZ-score and TLCO/VAZ-score above LLN did not differ statistically by primary symptom to limit exercise (P-value for F-test 0.167, 0.207 and 0.612, respectively). Output of the ANOVA is shown in S2 Output.)"

And (Discussion, page 17, line 294 -- 298):

"In patients with reduced lung function from COPD, associations between degree of dyspnea and indices of ventilatory limitation to exercise have been reported \[32\]. In contrast, we did not find FEV1Z-score, TLCOZ-score or TLCO/VAZ-score above LLN to be associated with the primary symptom to limit exercise in this cohort of patients with CAD and a physiological response to exercise characterized by cardiovascular limitation."

7\) As with several of the points above, it is recognized that this data is not available - but the lack of O2 pulse data and chronotropic slopes are a problem since they would provide important insights for variations in VO2peak, the contributions of underlying cardiac dysfunction, and the relative effects of BB use.

Response:

This is a timely recognized limitation by the reviewer, as acknowledged in the manuscript (Discussion, page 17, line 302 -- 305):

"Comprehensive evaluation of individual CPET responses including oxygen pulse (O2pulse) vs. time, HR vs. VO2 and VO2/work rate (WR) slope would likely have contributed to distinguish ischemic from non-ischemic physiologic pattern of cardiovascular limitation"

And (line 305 -- 307):

"Unfortunately, only data obtained at maximal exercise were available due to technical problems after the initial data extraction process"

In an attempt to address this limitation sensitivity analysis were performed (Discussion, page 17, line 307 -- 310):

"compared to the main analyses, the sensitivity analyses showed similar associations of FEV1Z-score, TLCOZ-score and TLCO/VAZ-score above LLN with VO2peak among patients with exercise induced ECG changes from rest (ST segment morphology or increased frequency of extrasystoles) suggestive of myocardial ischemia"

Betablocker treatment was included as a categorical, dichotomous variable in the final regression models and reported results are therefore adjusted for this.

In the end, I think that the lack of inclusion in the analyses of such a large amount of important data that could affect VO2peak limits the ability to draw conclusions on the association of normal range lung function variations and VO2.

Response:

We agree, and hope these limitations are now more thoroughly addressed in the revised version of the manuscript.

Reviewer \#2: Thank you for the opportunity to review this manuscript. The authors are to be commended for their production of a well-written and interesting study. The purpose of this study was to examine in a group of coronary artery disease (CAD) patients the relationship between individuals with 'normal' lung function (FEV1) and gas exchange (TLCO) and peak oxygen uptake (V̇O2peak). This work continues of from work previously published by the group in healthy older individuals. Overall I think this manuscript provides further important data on the importance of a potential pulmonary contribution to V̇O2peak despite individuals have essentially normal resting lung function and diffusion capacity. I have outlined some minor and specific comments for the authors to consider below. In particular I think it is important to not rule out changes that occur during exercise, which may limit peak exercise performance.

Minor Comments

1\. What about the changes in lung function and diffusion capacity during exercise -- have the authors considered these as a potential limitation -- despite normal resting values?

a\. Whilst the authors found that resting ventilatory reserve was not limited what about other possible ventilatory limitations during exercise such as expiratory flow limitation and or dynamic hyperinflation that may explain the ventilatory limitation? Whilst these dynamic changes were not recorded during the study -- could they have played a part in the limitation.

b\. Likewise whilst resting TLCO appeared normal -what about the potential limitations of pulmonary capillary blood volume (VC) and alveolar-capillary conductance (DM) at rest and during exercise. Changes in pulmonary diffusion during exercise have been shown to be related to exercise capacity in heart failure with reduced (HFrEF) and preserved (HFpEF) exercise capacity (- see Olson et al J Car Failure, 2006. 299-306; and JACC Heart Failure, 2016. 490-8). Whilst this is in well-defined HF populations, blunted changes in TLCO do occur during exercise which may account for some degree of limitation. Appreciate the authors did not make these measurements during exercise, these dynamic changes (like those of lung function) may have played a part in the limitation.

Response:

As questioned by the reviewer, we have also speculated on potential mechanisms linking lung function measures obtained at rest and VO2peak in these patients.

In this study, ventilatory reserve was traditionally defined as (1 --VE/MVV) at peak exercise. MVV was indirectly calculated as FEV1 x 40. We agree that ventilatory reserve, although a commonly used indicator of ventilatory limitation, is somewhat limited by the uncertainty of estimating maximal ventilatory capacity. Evaluation of exercise induced expiratory flow limitation, with dymamic hyperinflation and encroachment on the capacity for tidal volume expansion, by comparing maximal tidal flow volume curve vs. exercise tidal flow volume curves may certainly complement measurements of ventilatory reserve in assessment of ventilatory limitation. However, preserved/high ventilatory reserve is expected in patients with both normal ventilatory capacity and low ventilatory demand. In turn ventilatory demand is determined by both metabolic demand (VO2peak) and ventilatory efficiency. Ventilatory inefficiency designates increased dead space ventilation from intreased V/Q heterogeneity due to either nonuniform ventilation (airway disease) and/or nonuniform perfusion (pulmonary parenchyma and/or vascular disease).

Due to the combination of normal dynamic lung volume and diffusing capacity with low metabolic demand (VO2peak) from cardiovascular limitation in these patients, we consider exercise induced expiratory flow limitation, with associated unfavorable ventilatory consequences (i.e. ventilatory limitiation) unlikely.

In the revised version of the manuscript, this argument is conveyed by comparing the ventilatory demand vs. capacity relationship in our study population with mechanisms of ventilatory contribution to exercise limitation in highly trained athletes affected by EIAH (Discussion, page 15, line 238 -- 254):

"Ventilatory contribution to exercise limitation has been suggested in healthy individuals characterized by high metabolic demands \[26\]. In highly trained athletes performing exercise at sea level, high VO2peak may require levels of ventilation approaching maximal capacity, leading to exercise induced expiratory flow limitation, dynamic hyperinflation and mechanical constraints on tidal volume expansion. Inadequate hyperventilatory responses in athletes may interact with increased heterogeneity in distribution of ventilation/perfusion ratios and/or diffusion limitation causing exercise induced arterial hypoxemia (EIAH) (27). Compared to healthy subjects and trained athletes in particular, patients with CAD may have exercise intolerance \[6\] and reduced VO2peak due to symptomatic disease and/or deconditioning from physical inactivity. Lower VO2peak from cardiovascular limitation reduces the need for oxygen transport by the pulmonary system. In this study the patients had high RERpeak (1.19 ± 0.11) consistent with physiological responses to exercise characteristic of cardiovascular limitation. Additionally we found preserved VR, indicating low ventilatory demand at peak exercise relative to maximal ventilatory capacity, in the majority of patients (94%) as well as high SpO2min (95.9 ± 1.4%). Therefore, the positive associations of FEV1, TLCO and TLCO/VA above LLN with VO2peak are not likely to be explained by ventilatory limitation or abnormal gas exchange in patients with CAD."

In the revised version of the manuscript we have also emphasized that the physiological response to exercise in these patients is consistent with cardiovascular limitation (Discussion, page 15, line 248 -- 250):

"In this study the patients had high RERpeak (1.19 ± 0.11) consistent with physiological responses to exercise characteristic of cardiovascular limitation."

And (Discussion, page 14, line 230 -- 232):

"In this study we found dynamic lung volume, measured by FEV1 and lung diffusing capacity, measured by both TLCO and TLCO/VA, above LLN to be positively associated with VO2peak in non-obstructive patients with CAD and exercise intolerance from cardiovascular limitation."

And (Conclusions, page 19, line 335 -- 337):

"Dynamic lung volume, measured by FEV1 and lung diffusing capacity, measured by TLCO and TLCO/VA, above LLN are positively associated with VO2peak in non-obstructive patients with CAD and exercise intolerance from cardiovascular limitation."

We fully agree with the reviewer that further study of exercise induced changes in lung diffusing capacity, both VC and DM components, would be highly interesting. Although tempting, we do feel an obligation not to promote speculation that is not sufficiently supported by the data in this observational study. In an attempt to balance hypotheses and caution, the manuscript has been revised to include the following statement (Discussion, page 15 -- 16, line 262 -- 266):

"However, finding positive associations of FEV1, TLCO and TLCO/VA above LLN with VO2peak in this study, we may hypothesize exercise induced interactions between the pulmonary and the cardiovascular system, affecting overall capacity of the oxygen transport chain even when lung function is normal in patients with CAD and exercise intolerance from cardiovascular limitation."

2\. The a priori models tested included age and height. Whilst the body mass index appears normal, what about the impact of obesity -- could this not be a confounder, particularly in a coronary artery disease (CAD) population where this is indeed a risk factor?

Response:

We have taken note of the reviewer\`s proposal and adjusted the analyses for weight by exchanging the height variable against BMI as a covariate (Materials and methods, Statistical analyses, page 8, line 148 -- 149:

"Potential confounders were considered and four models are presented: 1) Crude associations; 2) Adjusted for sex, age and body mass index (BMI)"

Specific Comments

1\. Line 103: Was reversibility testing performed on all participants? If reversibility was detected were these participants excluded as this would have suggested presence of underlying obstructive disease?

Response:

In this study population only four patients had reversibility testing performed. In one of these patients, significant reversibility, i.e. an increase in FEV1 ≥ 200 ml and 12% post-bronchidolator, was detected. In the revised version of the manuscript, this patient is now excluded. The revised manuscript is specified accordingly (Materials amd methods, Study population, page 5 -- 6, line 95 -- 97):

"In four patients reversibility testing was performed. One patient was excluded due to significant reversibility, defined by a postbronchodilator increase in FEV1 ≥ 200 ml and 12%"

And (Materials amd methods, Pulmonary function tests, page 6, line 106 -- 107):

"In the three patients who had reversibility testing performed (non-significant), the highest FEV1 from pre- or postbronchodilator measurement was chosen."

2\. Please provide the end exercise RPE data -- was this different between groups?

Response:

Unfortunately, in this patient cohort, end exercise RPE data was not recorded. The patients were only asked to report primary reason for test termination and we are unable to meet the request.

3\. What was the range of V̇O2peak data and the range of FEV1/DLCO data. Recommend that the authors provide a figure of the relationship between V̇O2peak and FEV1/DLCO.

Response:

The results reported in this study are from multiple linear regression models and unfortunately not easily portrayed in a summarizing figure.

As requested by the reviewer, we have provided simple scatterplots of FEV1Z-score, TLCOZ-score and TLCO/VAZ-score by VO2peak and included these figures in the supporting information (Results, page 13, line 205 -- 206):

"Simple scatter plots of FEV1Z-score, TLCOZ-score and TLCO/VAZ-score by VO2peak are shown in S3 Figure, S4 Figure and S5 Figure, respectively."
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes
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If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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